Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PCI Announces Capital Investment in Rockford Facilities

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Leading pharmaceutical packaging firm investing in support of business growth.

Packaging Coordinators Inc (PCI) has announced further investment in its Rockford facilities in support of business growth and expansion.

The company acquired AndersonBrecon Inc. in May of this year and is adding additional equipment capacity and facilities infrastructure through capital investment, as well as hiring in support of business growth.

The company provides packaging services for pharmaceutical and healthcare products, working with leading Pharmaceutical and Biotech companies to bring lifesaving medicines to patients.

PCI operates 9 facilities in the greater Rockford, Illinois area totaling over 1 million square feet and employing over 1,300 highly trained associates.

PCI is owned by an entity formed by affiliates of lead investor Frazier Healthcare, a leading provider of growth equity and venture capital to high growth and emerging healthcare service and Biotech companies.

Continued Growth and Expansion
PCI’s Rockford location is experiencing its fourth straight year of significant growth. The company is experiencing substantial growth in 2013, which is anticipated to continue in 2014 and beyond.

In support of this growth, PCI has hired approximately 160 associates since January of 2012. Positions added include hourly, skilled labor, as well as management.

In addition to hiring, the company is looking to support new business by expanding its machine capacity, warehousing, and facilities infrastructure. PCI has added multiple blister packaging and bottling lines to meet increased demand in Ethical (prescription) and Over-the-Counter pharmaceutical markets and plans additional investment in this area.

The company is also investing in support of growth markets including commercial Biotech medicines and Clinical (Investigational) medicines.

Capital investments include expansion of on-site refrigerated Cold Chain storage capacity at 2 – 8° Celsius, -20° Celsius, and -80° Celsius.

A History Of Investment
The company opened a stand-alone potent compound packaging facility in 2010 and a new Clinical (Investigational) medicines packaging facility in 2011.

PCI’s largest Rockford facility, located at the Greater Rockford Industrial Park, was most recently expanded in 2008 and comprises over 720,000 square feet.

PCI’s North American and European sites feature state-of-the-art packaging facilities and cutting edge technologies, supporting very recognizable brands in the global healthcare market.

The company packages medicines destined for patients spanning over 100 countries across the globe. PCI’s headquarters in Philadelphia, PA employs approximately 475 associates.

A facility in Woodstock, IL employs approximately 125 additional associates. PCI’s domestic locations are complemented by four packaging sites in Wales, which currently employ approximately 300 associates, mainly in support of pharmaceutical products for the European region.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Definitive Agreement to Acquire Penn Pharma
PCI’s expands service offering with acquisition of Penn Pharma.
Thursday, July 31, 2014
Peter Belden Named General Manager of PCI Rockford Facilities
Belden returns to PCI North America to manage Rockford, IL operations.
Monday, September 02, 2013
Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Computerized Flexible Needles Prove Themselves in Biological Tissue
The advantage of the system is that you can avoid obstacles with the needles or critical tissues and that the system during the insertion of the needle in real time can adjust the path if, for example, the tissue deforms.
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Overdose of Vitamin D in Teenagers May Lead to Increased Cholesterol Levels
Dosing obese teens with vitamin D shows no benefits for their heart health or diabetes risk, and could have the unintended consequences of increasing cholesterol and fat-storing triglycerides. These are the latest findings in a series of Mayo Clinic studies in childhood obesity.
Phase 2 Trials Underway for New Single Dose Malaria Treatment
The new drug, which prevents the malaria parasite from reproducing and spreading, is now undergoing Phase II clinical trials in humans.
Promising Drug for Parkinson's Disease
A drug which has already been in use for decades to treat liver disease could be an effective treatment to slow down progression of Parkinson’s disease, scientists from the University of Sheffield have discovered.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!